CACI (CACI) Q1 2027 Earnings Call Transcript

CACI reported first-quarter FY2027 revenue of $2.47 billion, up 8.2% year over year, with adjusted diluted EPS of $7.66, up 11.8%, and EBITDA margin expanding 160 basis points to 13.3%. The company raised FY2027 revenue guidance by $50 million to $10.7–$10.9 billion and increased adjusted net income and EPS guidance; free cash flow guidance remained at least $900 million. Awards totaled $4.8 billion (2.0x book-to-bill), funded backlog grew 14.8%, and 94% of expected FY2027 revenue is tied to existing programs. Management cited sluggish award decisions and inflation and extended lead times for memory, semiconductors, and rare earths as risks.

Analysis

CACI’s strongest near-term asset is revenue visibility, but visibility is not the same as accelerating demand: a high share of work already on contract dampens downside this year while shifting the debate to execution, funded task orders, and margin conversion. The 2.0x book-to-bill is supportive, yet award duration and extensions can inflate coverage without pulling forward equivalent revenue; distinguish funded backlog from total backlog in subsequent disclosures.

The key earnings risk is margin normalization. A 13.3% quarter against a high-12% full-year framework leaves room for mix and program execution to reverse, especially as management describes a more gradual second-half ramp. Fixed-price work can support margins when scope is understood, but component inflation and long lead times create a timing mismatch: CACI may fund inventory and production capacity before repricing or customer cash arrives. That makes quarterly FCF and working capital more informative than headline EPS. Leverage reduction is a catalyst for renewed capital-allocation flexibility, but depends on the reaffirmed cash target being delivered.

In the next 1–3 months, watch the December CR deadline and whether delayed awards convert to funded starts; in 6–18 months, Rochester capacity and space/EW production must translate into throughput rather than simply higher working capital. The early-2027 investor day is a potential estimate-reset catalyst. Management’s technology and AI differentiation is plausible, not yet proof of durable incremental returns; customer reinvestment of savings could favor scope growth over margin capture.

No price or valuation data are supplied, so the earnings signal alone does not justify chasing a gap. The relative thesis weakens if CACI’s organic growth or funded-backlog growth stalls, full-year margin guidance is cut, or FCF misses the $900 million floor; supply constraints or a prolonged procurement slowdown are additional downside triggers.

Key Decisions for Investors

• Avoid chasing the immediate post-earnings move without checking the price reaction and relative valuation. If CACI holds its earnings reaction while funded backlog and guidance remain intact, consider a modest long CACI versus an equal-weight short basket of Leidos (LDOS), Booz Allen (BAH), and SAIC (SAIC); this is a relative execution thesis, not a claim that peers have weaker fundamentals.
• For the next quarter, monitor funded backlog, task-order starts, DSO/working-capital movement, and fixed-price program performance. Treat a deterioration in these measures as an earlier warning than total backlog or adjusted EPS.
• Use the December CR deadline and early-2027 investor day as catalysts, not assumptions: a procurement delay that pushes expected starts or a lower three-year growth/margin outlook would invalidate the near-term positive setup.
• Do not underwrite incremental exposure to GitLab or SpaceX from their mentions on the call: the transcript does not establish material revenue or awards for either. Verify contract scope and financial contribution before attributing upside.